Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BP 1002

Next Previous
Drug Profile

BP 1002

Alternative Names: BP-100-1.02; BP-1002; L-Bcl-2 antisense oligonucleotide; Liposomal Bcl-2; Liposomal Bcl-2 antisense

Latest Information Update: 19 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Proto-oncogene proteins c-bcl-2 expresssion inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 15 Apr 2024 Bio-Path Holdings has patent protection for P-ethoxy nucleic acids for BCL2 inhibition in Australia
  • 14 Dec 2023 Adverse events data from a phase I trial in in Acute myeloid leukaemia released by Bio-Path Holdings
  • 21 Nov 2023 Phase-I development in Peripheral-T-cell-lymphoma, Chronic lymphocytic leukaemia, Cutaneous T-cell lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma, Hodgkin's disease, Mantle-cell lymphoma, Marginal zone B-cell lymphoma, Waldenstrom's macroglobulinaemia (Late-stage disease, Monotherapy, Second-line therapy or greater) is still ongoing in USA (IV, Infusion) (NCT04072458)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top